http://oxfordpharmascience.com/


Oxford Pharmascience is a drug development company that re-develops approved drugs to make them better, safer and easier to take.

Oxford Pharmascience is using its proprietary oral drug delivery technologies to develop improved formulations of non-steroidal anti-inflammatory drugs (NSAIDs) and statins for global markets.

The Company's risk-diversified pipeline of prescription and OTC medicines is focused on cardiovascular disease and pain relief indications. Since the products incorporate previously approved drugs, this reduces risk and results in a simplified drug development regulatory pathway allowing less expensive development programs and faster access to market.

The Company has also commercialized calcium/vitamin D chews that taste better and dissolve faster than currently available regular formats. These products are now marketed in the UK, Middle East and Brazil.

Oxford Pharmascience is located in the UK and is led by a highly experienced management team that directs and manages the outsourcing of its development; pre-clinical and clinical programs; and manufacturing to a trusted network of partners and suppliers.

The Company commercializes its portfolio of product opportunities through out-licensing to leading pharmaceutical companies worldwide. Currently the Company has partnerships with Aché Laboratories and Bayer.

Oxford Pharmascience (LON:OXP) was established by a team of entrepreneurs in 2008 and is a publicly listed company on London's Alternative Investment Market (AIM), with a strong blue chip investor base.

As of last trade, Oxford Pharmascience Group PLC (OXP:LSE) traded at 11.45, 257.81% above the 52 week low of 3.20 set on Dec 10, 2014.

PK Results for OXPzero Naproxen vs. Naprosyn
RNS
RNS Number : 9880M
Oxford Pharmascience Group PLC
13 May 2015

Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")



Pharmacokinetic (PK) Study Results
for OXPzero™ Naproxen vs. Naprosyn®



Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, is pleased to announce the positive full results of the pilot comparative pharmacokinetic (PK) study for OXPzeroTM Naproxen (OXP005), which - based on mean values - demonstrates an immediate release profile and bioequivalence to standard US and EU naproxen treatment.



OXP005 delivers 250mg of reduced gastric irritation naproxen via the Company's patent protected OXPzero™ technology. The full results of the study follow on from the headline data previously announced on 27 March.



The two-arm, pilot PK study was conducted in 10 healthy adult participants with each subject receiving both the OXP005 and the Naprosyn® treatments in a crossover design. The PK data show that all subjects had equivalent absorption of naproxen from OXP005 and of Naprosyn®, as indicated by area under the curve (AUC), with OXP005 being 100.5% of that observed for Naprosyn®. Mean maximum concentrations (Cmax) were 82.8% of that observed with Naprosyn®. In addition, both the mean half-life, time to maximum concentration and time to first measurable naproxen levels for OXP005 were comparable to Naprosyn®.



The amount of naproxen contained within the OXP005 tablets used for the PK trial was slightly low at 95.5% of the target naproxen dose, due to low tablet weight. Adjusting the PK results to account for the actual naproxen dose in both products tested provides mean relative values for absorption (from the AUC measurements) and maximum concentration (Cmax) of 102.8% and 84.3% respectively. The mean values for AUC and Cmax are within the guidelines for bioequivalence (80.0 to 125.0%). The fully powered bioequivalence study in later development will be designed to show that the 90% confidence intervals also fall within these limits, as per the FDA and EU guidelines.



These pilot PK study results demonstrate that, based on mean values, OXP005 is bioequivalent to Naprosyn® and therefore the Company is progressing to a proof of concept endoscopy study comparing the extent of gastroduodenal irritation between the OXP005 and Naprosyn. Dosing for this study is on track to start imminently with approvals required for the study in place and potential study subjects identified.



Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most widely used classes of drugs, with more than 30 million users worldwide consuming NSAIDs each day and combined annual sales in excess of $12 billion (source: Evaluate Pharma). However, chronic use of NSAIDs causes well-documented gastrointestinal side effects, including ulcers and bleeding, and leads to significant morbidity and mortality in a substantial number of patients, with significant healthcare costs arising as a result of these side effects. The OXPzero™ platform technology reduces these risks and is being selectively applied to the most commonly used molecules in the NSAID category, namely ibuprofen, naproxen, diclofenac and aspirin.



Naproxen is an important NSAID with total sales of c $1bn at MSP (manufacturers' selling prices), mostly in North America.1 Naproxen was first approved for prescription use in the US in 1976 and was made available for OTC use as Aleve® (naproxen sodium 220 mg) in the US in 1994. Outside North America, naproxen is mostly used by prescription only. While naproxen has a somewhat higher risk of causing adverse GI effects as compared with ibuprofen2 it has some distinct advantages: Naproxen offers longer lasting relief and therefore requires less frequent dosing. Importantly, based on published analysis, naproxen is thought to have a reduced risk of cardiovascular events than all other NSAIDs3. It is therefore the preferred NSAID for long-term use in people with a high risk of cardiovascular complications4 and increasingly the preferred prescription option for patients with chronic conditions commonly treated with NSAIDs.





Marcelo Bravo, Chief Executive Officer of Oxford Pharmascience commented:



"These pilot study results with OXP005 support further development of our gastric safe naproxen and support our vision to revolutionise the NSAID treatment market. We are advancing development of a new pain relief treatment option for patients that offers improved gastrointestinal safety over the well-known NSAIDs, leading with the NSAID offering the safest cardiovascular profile, naproxen."

Ibuprofen progressing to proof of concept trial
RNS
RNS Number : 2857N
Oxford Pharmascience Group PLC
15 May 2015



Chewable Form of OXPzero™ Ibuprofen progressing to Proof-of-Concept Clinical Trial



Oxford Pharmascience Group Plc (AIM: OXP), the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces completion of the development of an immediate release, taste masked, chewable 400mg ibuprofen product that is now ready for clinical evaluation. OXPzeroTM Ibuprofen (OXP001) delivers 400mg of reduced gastric irritation ibuprofen via the Company's patent protected OXPzero™ technology.



In January 2015, the Company announced that OXPzero™ Ibuprofen had been successfully optimised to deliver an immediate release tablet that demonstrated in vitro equivalence to standard Brufen® (400mg Ibuprofen tablet) and that a proof-of-concept clinical study with the optimised tablet was expected to begin in Q2 2015.



The Company has now developed a chewable 400mg ibuprofen tablet that is not only expected to reduce the risk of GI irritation but also to taste mask the bitter taste of the ibuprofen via OXP's patent protected OXPzero™ technology. Patient compliance to long-term therapy for chronic illnesses is a key issue and is reported to be around only 50% in developed countries.1 Providing patients with a GI safe treatment option, delivered in an easier to take dosing mechanism is believed to be a significant advantage in the non-steroidal anti-inflammatory drug (NSAID) treatment arena. The Company believes this would lead to improved patient compliance amongst long-term usage patients.



The Company has now decided to proceed to a proof-of-concept clinical trial with the chewable tablet and is planning to begin dosing in July 2015 with headline pharmacokinetic data also expected in July 2015. Endoscopy data to prove the reduction in GI irritation is due to follow in late Q3/early Q4 2015.



NSAIDs are one of the most widely used classes of drugs, with combined annual sales in excess of $12bn2 and more than 30 million users worldwide consuming NSAIDs each day3. Chronic use of NSAIDs causes well-documented GI side effects, including ulcers and bleeding, and leads to significant morbidity and mortality in a substantial number of patients, with significant associated healthcare costs. The OXPzero™ platform technology reduces these risks and is being selectively applied to the most commonly used NSAID molecules, namely ibuprofen, naproxen and diclofenac for pain and inflammation and aspirin for primary and secondary prevention of cardiovascular disease.



Ibuprofen is currently the dominant NSAID molecule in the pain relief and anti-inflammatory sector. Worldwide sales of Ibuprofen are in excess of $4bn per annum at manufacturers selling prices2. The Company hopes to provide the market with a much differentiated product, offering both a GI safer alternative to current NSAIDs and varied finished product forms to improve compliance rates.



Marcelo Bravo, Chief Executive Officer, commented:

"The development and progression of a chewable taste masked ibuprofen tablet to the clinic will not only provide the data to further confirm the GI irritation reduction benefit of the OXPzero™ technology but will also provide evidence in a clinical setting of its taste masking ability. Successful data from this study alongside data from OXPzero™ Naproxen will provide a robust data package moving forward into commercialisation of these assets."



Sources

1. WHO Report "Adherence to long-term therapies. Evidence for action. 2003.

2. Evaluate Pharma

3. Black Swan Analysis Ltd - Market Evaluation for OXPZero™ technology to improve compliance with leading NSAID brands, November 2013 (commissioned by OXP)

Initiation of Pilot Clinical Study for Naproxen
RNS
RNS Number : 4078N
Oxford Pharmascience Group PLC
18 May 2015

Oxford Pharmascience Group plc

("Oxford Pharmascience" or the "Company")

Initiation of Pilot Clinical Study
for Reduced Gastro-Intestinal Irritation Naproxen


Oxford Pharmascience Group Plc (AIM: OXP), the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces the initiation of dosing in its pilot clinical study of 250mg OXPzeroTM Naproxen (OXP005). OXP005 uses Oxford Pharmascience's patented OXPzero™ technology in an immediate release oral formulation and aims to provide a significantly reduced gastrointestinal (GI) side effect profile compared to standard naproxen tablets.



Following on from the recent announcement of the successful proof-of-concept pharmacokinetic (PK) study, the Company is pleased to announce that it has progressed to an endoscopic evaluation study to prove the reduced GI irritation of OXP005. The purpose of this Phase I, randomised, controlled pilot study is to assess the severity of upper GI damage via endoscopic assessment following 7 days treatment of 1 g/day naproxen dosed as either OXP005 or Naprosyn®. Headline results are expected to be released in late Q2/early Q3 2015. Further details about the study can be found at www.ClinicalTrials.gov.



Naproxen currently has worldwide sales of c.$1bn1 and is one of the most important molecules in the NSAID category due to a number of factors:

· its pain relief and anti-inflammatory effect are longer lasting than other NSAID molecules allowing for less frequent dosing regimes, which aids patient compliance; and

· its use is also associated with a lower incidence of cardiovascular complications compared to all other NSAIDs3. It is therefore the preferred NSAID for long-term use in people with a high risk of cardiovascular complications4.

However, the widespread use of Naproxen is hampered by the higher risk of GI irritation relative to Ibuprofen3. Accordingly, if GI irritation is reduced, OXP005 could provide a highly appealing combination of long lasting pain relief, lower cardiovascular risk profile and reduced GI irritation.



Marcelo Bravo, Chief Executive Officer, commented:

"The development of GI safer NSAIDs is a key priority for Oxford Pharmascience and we are very pleased to have commenced endoscopic evaluation of OXPzero™ Naproxen. Successful study data will confirm the results observed last year with OXPzero™ Ibuprofen demonstrating the class effect of the technology and putting the company in a strong position going into partnering discussions later this year."

NSAIDs are one of the most widely used classes of drugs, with combined annual sales in excess of $12bn1 and more than 30 million users worldwide consuming NSAIDs each day2. Chronic use of NSAIDs causes well-documented GI side effects, including ulcers and bleeding, and leads to significant morbidity and mortality in a substantial number of patients, with significant associated healthcare costs. The OXPzero™ platform technology reduces these risks and is being selectively applied to the most commonly used NSAID molecules, namely ibuprofen, naproxen and diclofenac for pain and inflammation and aspirin for primary and secondary prevention of cardiovascular disease.



Sources

1. Evaluate Pharma

2. Black Swan Analysis Ltd - Market Evaluation for OXPZero™ technology to improve compliance with leading NSAID brands, November 2013 (commissioned by OXP)

3. Lancet. 2013 Aug 31; 382(9894): 769-779. doi: 10.1016/S0140-6736(13)60900-9

4. American College of Gastroenterology - Ulcers and Gastrointestinal Bleeding: Protecting Your Health

Proactive investor -Oxford Pharmascience (LON:OXP), down 8.4%. The shares slipped a penny to 10.875p after the company said it had raised £20mln by placing shares at 10p a pop.

Shares - Why Oxford Pharmascience wants £20m


Upgrades are on the way for drug re-developer Oxford Pharmascience (OXP:AIM) as it raises £20 million to hone its pipeline.

The £115.6 million cap sold 200 million shares at 10p each to institutions. The stock only falls 3.1% to 11.5p following the deal, despite the shares selling for a near 16% discount to Monday’s closing price.

Oxford initially targeted £5 million, but demand was high with investors backing the company’s story of taking approved drugs and removing their side effects or making them easier to take.

Shares can reveal that around half the shares were bought by star fund manager Neil Woodford, who topped up his existing stake in the business to more than 30%. While going over the 30%-mark this would normally spark a mandatory bid for the entire business, although the investment expert has applied for a waiver from this obligation.

Web - Oxford Pharmascience - 2 June 2015

The proceeds will be used to develop Oxford’s pipeline and investigate new therapeutic uses for its technology. The cash will also strengthen its hand during commercial negotiations.

The deal is conditional on a shareholder vote on 24 June, when analysts at broker N+1 Singer say they will update their forecasts.

The main beneficially of the placing will be Oxford’s OXPzero Aspirin painkiller for cardiovascular disease sufferers, which is being designed to reduce gastric irritation while removing its taste. Alongside development, money will be spent on manufacturing and clinical trials.

Developing its statin product is also on the agenda, while a version of an ibuprofen tablet is expected to generate clinical proof of reducing gastric irritation this year.

On Monday, Oxford Pharmascience Group PLC (OXP:LSE) closed at 13.38, 317.97% above the 52 week low of 3.20 set on Dec 10, 2014.

Superb chart.

Initiation of Pilot Clinical Study for Ibuprofen
RNS
RNS Number : 1411T
Oxford Pharmascience Group PLC
16 July 2015

Oxford Pharmascience Group plc

("Oxford Pharmascience" or the "Company")



Initiation of Pilot Clinical Study
for Reduced Gastro-Intestinal Irritation Ibuprofen



Oxford Pharmascience Group plc (AIM: OXP), the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces the initiation of dosing in its second pilot clinical study of 400mg OXPzeroTM Ibuprofen (OXP001) to assess a comparable PK profile.



OXP001 is an optimised, chewable, 400mg ibuprofen tablet that is expected to reduce the risk of gastro-intestinal ("GI") irritation from the ibuprofen and to taste-mask its bitter taste via OXP's patent protected OXPzero™ technology. Patient compliance to long-term therapy for chronic illnesses is a key issue and is reported to be around only 50% in developed countries.1 Providing patients with a gastro-intestinally safe treatment option, delivered in an easier to take dosage form, is believed to be a significant advantage in the non-steroidal anti-inflammatory drug (NSAID) treatment arena. The Company believes this would lead to improved patient compliance amongst long-term usage patients.



Last year the Company announced results from the first pilot study with a non-optimised OXP001 tablet. Results showed a significant reduction in gastro-intestinal irritation with OXP001 compared to Brufen®, however the pharmacokinetic profile of OXP001 showed a slower and incomplete release of ibuprofen. The OXPzeroTM Ibuprofen and the tablet formulation have since been optimised to provide immediate and complete drug release in vitro. This second proof-of-concept study is designed to compare the pharmacokinetic profile of OXP001 immediate release tablets with generic Brufen®, and with a second stage of this trial to confirm the reduction in gastro-intestinal irritation as measured by endoscopy.



The Company also reports that headline data from the recently conducted pilot clinical study with OXPzeroTM Naproxen (OXP005) will be available by the end of July 2015. Further details will be published in due course.



NSAIDs are one of the most widely used classes of drugs, with combined annual sales in excess of $12bn2 and more than 30 million users worldwide consuming NSAIDs each day3. Ibuprofen is currently the dominant NSAID molecule in the pain relief and anti-inflammatory sector. Worldwide sales of Ibuprofen are in excess of $4bn per annum at manufacturers selling prices2. Chronic use of NSAIDs causes well-documented GI side effects, including ulcers and bleeding, and leads to significant morbidity and mortality in a substantial number of patients, with significant associated healthcare costs. The OXPzero™ platform technology reduces these risks and is being selectively applied to the most commonly used NSAID molecules, namely ibuprofen, naproxen and diclofenac for pain and inflammation and aspirin for primary and secondary prevention of cardiovascular disease.



Marcelo Bravo, Chief Executive Officer, commented:

"We are pleased to have overcome the significant technical hurdles in the development of an immediate release, chewable, taste masked OXPzeroTM Ibuprofen tablet. Progressing this optimised OXP001 product to the clinic will provide the data to confirm further the benefits of the OXPzero™ technology including reduced GI irritation."





Sources

1. WHO Report "Adherence to long-term therapies. Evidence for action." 2003.

2. Evaluate Pharma

3. Black Swan Analysis Ltd - Market Evaluation for OXPzero™ technology to improve compliance with leading NSAID brands, November 2013 (commissioned by OXP)

One worth watching for a new entry point.


Results from Pilot Clinical Study of OXP500
RNS
RNS Number : 6490U
Oxford Pharmascience Group PLC
31 July 2015

Oxford Pharmascience Group plc

("Oxford Pharmascience" or the "Company")



Encouraging Results
from Pilot Clinical Study of OXPzeroTM Naproxen (OXP005)



Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces the results of its proof of concept clinical study to determine the extent of upper gastrointestinal (GI) tract irritation of its OXPzeroTM 250mg tablet ("OXP005") compared with the Naprosyn® 250mg (Naproxen) tablet by endoscopic evaluation. Further details are included below and more information can be found at www.ClinicalTrials.gov.



HIGHLIGHTS



• Achieved a statistically significant reduction in the number of upper gastrointestinal erosions observed by endoscopy after administration of OXP005 compared to Naprosyn® in healthy volunteers.



• Lanza score (a clinical rating score of gastrointestinal irritation in the stomach and duodenum on endoscopic evaluation) was comparable between OXP005 and Naprosyn®.



• PK data confirms bioequivalence of OXP005 and Naprosyn® at Day 1 and Day 7.



• The Company believes the technology can be further optimized specifically for naproxen and a programme to define the improved product is being initiated.



The primary endpoints of the study were 1. a comparison of the overall Lanza score and 2. a comparison of the total number of erosions observed in the stomach and duodenum.



In the study both OXP005 and Naprosyn® exhibited a similar Lanza score while OXP005 exhibits a moderate (c. 26%) reduction in total erosions, albeit at a non statistically significant level.



OXP005 meets the primary endpoint of reduced erosions exhibiting a major (c. 38%) reduction of total erosions which is statistically significant after accounting for ineligible subjects. While OXP005 is reducing the number of erosions, the Lanza score endpoint was not met.



The pharmacokinetic (PK) data obtained on Day 1 of the study confirm results observed in the first phase of the study and also confirm that on Day 7 OXP005 is fully bioequivalent to Naprosyn® based on mean values of core PK measures as detailed below.



Oxford Pharmascience is encouraged by these results and believes that further work will bring the OXPzeroTM Naproxen technology to its full potential. OXP005 was a direct re-application of the technology as developed for ibuprofen, which is known to cause less upper GI irritation than naproxen.



The Company believes it can further improve these results by adapting OXPzero™ specifically for the naproxen molecule. In the past few months a significant understanding of the technology and its ability to be modified has been gained in the lab and through its clinical trial observations and this will be applied to reiterate with a reformulated OXP005.


Headline pharmacokinetic data from a further pilot clinical study of OXPZeroTM Ibuprofen (OXP001) in an optimized, chewable form, will be reported in the coming weeks.



The Company plans to begin partnering discussions in the coming months with opportunities evaluated on the basis of both current and anticipated data, with the aim of achieving the optimal commercial outcome and value for shareholders. The Company's strong balance sheet provides greater commercial flexibility as it enters these discussions, including to conduct further work to adapt the platform for naproxen.



Marcelo Bravo, Chief Executive Officer, commented:



"We are encouraged by these results and take confidence from the fact that we now have two clinical data sets for OXPzeroTM variants of major NSAIDs demonstrating reduced GI irritation. Ibuprofen and naproxen account for $4.8 billion of the total $12 billion global market. We are confident in the future potential of the OXPzeroTM platform as we implement the further work to be done to exploit the full potential of naproxen and provide further data to support commercial discussions. With additional funds on board to allow us to generate further data, and additional endoscopy data from our further pilot clinical study for ibuprofen expected by the end of October, the plan remains to commence partnering discussions with the aim of maximising future value for the Company and its shareholders.



We look forward to providing further updates on our development pipeline, including the OXPzeroTM NSAIDs programme and other OXPzeroTM applications and the OXPtargetTM SafestatTM programme and other OXPtargetTM applications."



Summary PK Data



OXP005 achieved mean relative values for absorption (Area Under the Curve, AUC) and maximum concentration (Cmax) of 101.9% and 86.1% respectively on Day 1 and 105.6% and 91.7% respectively on Day 7. The mean values for AUC and Cmax are within the guidelines for bioequivalence (80.0 to 125.0%).

Preliminary PK Data & Initiation of Further Study
RNS
RNS Number : 7988V
Oxford Pharmascience Group PLC
12 August 2015



Oxford Pharmascience Group plc

("Oxford Pharmascience" or the "Company")



Preliminary Pharmacokinetic Data and
Initiation of Pilot Clinical Study

to Demonstrate Improved GI Profile for OXPzero™ Ibuprofen



Oxford Pharmascience Group Plc (AIM: OXP), the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces that preliminary pharmacokinetic (PK) data confirms that OXP001(2) has successfully met its optimisation objectives for immediate release and complete drug absorption. The Company has commenced dosing in the second phase of the study, which seeks to prove the reduced gastro-intestinal (GI) irritation benefit of OXPzero™ Ibuprofen by endoscopic evaluation.



The randomized pilot PK study was a single-dose, two-arm UK study comparing the OXP001(2) 400mg chewable OXPzero™ Ibuprofen tablet and the reference Brufen® 400mg tablet (ibuprofen), in ten subjects. Preliminary PK data show comparable AUC (Area Under the Curve or total drug exposure over time) and tmax (time to reach maximum serum concentration) results, demonstrating that OXP001(2) is now a product with immediate and complete drug release characteristics. While the PK profile of the product appears to be similar to that of Brufen® on these measures, the maximum level of drug concentration in plasma (Cmax) appears to be lower compared to Brufen® but remains well within the range which the drug has therapeutic effect. The Company believes this preliminary PK data represents an acceptable clinical profile suitable for commercialisation. Additional PK data will be collected during the next phase of the study.



The taste masked benefit of OXPzero™ Ibuprofen was also assessed via subject interviews, during the first phase of this study, with consistent feedback confirming that the chewable tablets were tasteless, with none of the burn or after-taste issues associated with standard ibuprofen.



Following analysis of the preliminary PK data, the Company is proceeding to the second phase of the study, which aims to demonstrate a significantly reduced GI side effect profile compared to standard 400mg Brufen® tablets. The product to be tested, OXP001(2), is a 400mg chewable, taste masked, oral formulation of ibuprofen.



This phase of the study is a randomised, assessor-blinded, controlled pilot clinical study to assess the severity of upper GI damage via endoscopic assessment following 7 days' treatment of 2.4g/day of ibuprofen dosed as either OXP001(2) or Brufen®. A prior study in 2014 demonstrated significant GI side-effect benefits, compared to Brufen®, using an early version of OXP001 for which the PK profile has since been optimised for immediate release and complete drug absorption. Headline results on the second phase are expected to be released in Q4 2015, along with complete PK data and further taste masking assessments.



Marcelo Bravo, Chief Executive Officer, commented:

"We are pleased to confirm that OXP001(2) now achieves immediate release and complete drug absorption in vivo and that the taste masking benefit of the technology has been validated. We are confident the product is achieving release properties in line with the objective of delivering a reduction in GI irritation. Demonstrating that OXP001(2) achieves a significant reduction in GI erosions compared to Brufen® in this new formulation will validate OXPzero™ Ibuprofen as a disruptive compound in the major $4bn ibuprofen market."



Further details about the study can be found at www.ClinicalTrials.gov.

Listen: Preliminary PK Data & Initiation of Further Study

click here

Who Should Attend?Date:

Wednesday 25th May 2016

Venue:

Novotel Tower Bridge, London EC3N, 10 Pepys Street, London, EC3N 2NR

Event Timings:Sponsored by:

Making good progress in May.

For my own Info
Formerly Oxford NutraScience . . .they reformulate existing preparations to reduce risk . . . I guess the Old Name was likely to be associated with Nutrition, whereas they target Pain and other areas..... SP= 7.25p - almost doubled since early 2016 -late 2015.
Some Trials are underway - may explain the increased interest, etc.
EDIT (27Oct2016)- Spoke too soon...sp 3p-ish... Trial-delays...? -Or needing Trial-Cash?
EDIT(1Nov2016)- sp 2.13 - Is Ibrpru now in the Wild?... i.e. Others can use it? So it would not be an exclusive...
EDIT (11Jan2017)- sp 1.8p doesn't look like those Institutions ( at 10p, 2015) were betting their own money...
EDIT (10April2017)- fall-back to 1.9p - Oh dear.

Bought some earlier today

KEEP an EYE

OXP 2.225p ( 2.20/2.25p )

Large volume 40.4M at LSE and 3.3M at ISDX, share price bounce today after a fall from 7.75p this year and 13.50p last year. Cash rich £22M worth 1.82p, so 80% is in cash adn the rest of the company has almost no value.
video presentation from CEO

2.525p +0.25p

Going places now on a very narrow spread 2.50 v 2.55p
level 2 is 2 v 1
the last 2 days of large volume is working wonders for the share price now

2.525p +0.25p

level 2 of 2 v 1

Good post from Twitter group chat ........

Highlights

Substantive progress in commercialisation discussions regarding the Company's lead NSAID1 assets, OXPzeroTM Ibuprofen and OXPzeroTM Naproxen

Feedback has identified the key precursors to successful partnership outcomes, including:
additional platform development
clarity on regulatory pathway for over the counter (OTC) and Prescription (Rx) product approval

Significant progress advancing the OXPzeroTM technology platform:

Improvement of drug release in vitro
Scale-up and optimisation of the manufacturing process
Strengthening of the intellectual property (IP) portfolio

Planning to conduct small-scale exploratory pharmacokinetic (PK) trials to validate the in vivo performance of formulation improvements, with details to be announced separately in due course

Ongoing dialogue including the initiation of broader outreach to include the Rx market

Proceeding to seek pre-IND meetings with the US FDA to clarify US regulatory pathway

License per product would mean £20-30m upfront payment, Further sales milestone payments and mid teen royalty payments, Gastric safe NSAID's potential sales of over £500m

Marcelo Bravo, Chief Executive Officer, commented

We are very encouraged with the strong traction we are getting from some of the major potential partners in our discussions and we are also continuing to progress our other pipeline opportunities including Asprin and statins

Ibuprofen is currently the dominant NSAID molecule in the pain relief and anti-inflammatory sector with worldwide sales of Ibuprofen in excess of $5bn per annum. The Company has initiated contact with a number of large, global pharmaceutical companies with strategic interest in the ibuprofen market and is at an advanced stage of preparing information to proceed to the commercialisation phase with the OXPzeroTM Ibuprofen asset.

Large volume for the last few days

Below is the last holdings list of investor's over 3% and in the absence of a change of major holdings RNS assume is still current, they could now be adding and the free float looks tiny.

Woodford Investment Managers 401,597,920 33.31%
Mr R Griffiths 173,071,097 14.35%
David Norwood 105,938,633 8.79%
Marcelo Bravo 65,000,000 5.39%
Southern Fox Investments Ltd 51,000,000 4.23%
Henderson Global Investors 49,400,000 4.10%
Octopus Investments 42,140,345 3.50%
Aviva Investors 37,964,329 3.15%
Mr R Quested 37,247,753 3.09%

R&D Update
RNS
RNS Number : 6768O
Oxford Pharmascience Group PLC
09 November 2016
 
Oxford Pharmascience Group plc
("Oxford Pharmascience" or the "Company")
R&D Update
Oxford Pharmascience Group plc (AIM: OXP), the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take provides the following update on the development of its R&D pipeline.
OXPzeroTM
As reported within the interim results, the Company continues commercialisation discussions for its lead assets, OXPzeroTM Ibuprofen and OXPzeroTM Naproxen. In parallel, the Company has focused its technical activities on advancing the OXPzeroTM technology to affect and control release properties, scaling-up and optimising the manufacturing process and strengthening its intellectual property (IP) portfolio.
The Company has now completed preliminary laboratory work leading to the identification of OXPzeroTM platform technical modifications that alter the release properties and enable faster release of the NSAID. As a result of this work, the company has just filed a national application for a new patent in the UK with international filings to be expanded over the next two years as the application progresses, significantly strengthening the IP portfolio for its OXPzeroTM technology platform.
The Company will be now progressing to conduct UK based Phase I exploratory pharmacokinetic (PK) clinical studies to validate the in vivo performance of these technology improvements, focusing first on its lead compound OXPzeroTM Ibuprofen.  The OXPzeroTM Ibuprofen study will be split into three parts and will assess the PK profiles both at over-the-counter (OTC) and prescription (Rx) strength doses of standard ibuprofen against OXPzeroTM Ibuprofen and the lead technology modifications identified. Regulatory and Ethics submissions have been made for this study and dosing is expected to start early in 2017. In addition, pre-clinical evaluation of these technology modifications is ongoing using an innovative gastric mucosal cell model at the University of Newcastle to assess the effect of these technology modifications on gastric mucosal damage.
In parallel to this technical and clinical work, the Company is seeking clarity on the regulatory pathway for OTC and Rx OXPzeroTM NSAID products. The Company is now seeking advice from the US Food and Drug Administration (FDA) on the development pathway for the OTC and Rx OXPzeroTM Ibuprofen programmes. Pre-IND meeting requests have been submitted to the FDA for both the OTC and Rx variants; the Company has assembled a team of highly-experienced US and EU consultants to assist with these meetings which are expected to take place early in 2017. Obtaining clarity from the FDA on the regulatory pathway will be a major milestone to further facilitate partnering discussions for the key US market.
Other programmes
While the focus has been OXPzeroTM NSAIDs, the company also carried out development work to further its cardiovascular pipeline.
Following extensive process development work, OXPzeroTM Aspirin has been successfully manufactured at laboratory scale.  As the material produced by this process has not attained the required stability profile, a decision has been taken not to progress this programme further at this time
In our statins portfolio, development of a new colon-targeted formulation of atorvastatin is ongoing. The aim of this programme is to reduce the degree of cytochrome P450 metabolism in the upper GI tract, thereby reducing the formation of degradation products known to cause statin related side effects such as myalgia (muscle pain). A new formulation development and manufacturing contract facility has been appointed and development of a new salt form of atorvastatin with anticipated improved acid stability is ongoing.
Funding
 
Oxford Pharmascience remains well-funded to complete this next stage of work on clinical development and the regulatory pathway for its OXPzeroTM products, as well as the development work on atorvastatin, with cash balances as at 31 October 2016 of circa £22.6 million.
 
Commenting on the progress, CEO Marcelo Bravo said:
 
"In parallel to the ongoing commercial partnering activities, we are pleased to see OXPzeroTM Ibuprofen going back into the clinic and our OXPzeroTM NSAIDs IP protection being strengthened.  We look forward to receiving advice from the FDA on our over-the-counter and prescription OXPzeroTM Ibuprofen product development strategies."
This announcement contains inside information.